Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2019 Oct;51(4):1380-1391. doi: 10.4143/crt.2018.476. Epub 2019 Feb 18.
A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status.
The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases.
A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis.
This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
软组织肉瘤(STS)是一种罕见的癌症,占成人实体瘤的 1%。本研究旨在确定韩国患者局部和晚期 STS 的发病率、他们的治疗模式以及按疾病状态划分的患者生存率。
使用国家健康保险服务 2002 年至 2015 年的医疗数据定义 STS 患者队列。通过对包含局部和晚期 STS 病例的 STS 队列应用不同的算法,分析发病率、分布、肿瘤解剖位置、生存率(Kaplan-Meyer 生存函数)和治疗模式。
2007 年至 2014 年共诊断出 7813 例 STS 患者,其中 4307 例为局限性 STS,3506 例为晚期 STS。STS 的总发病率为每 100,000 人年 2.49 例:局限性 STS 为每 100,000 人年 1.37 例,晚期 STS 为每 100,000 人年 1.12 例。所有 STS 的 5 年生存率为 56.4%,局限性 STS 为 82.4%,晚期 STS 为 27.2%。一半的晚期 STS 患者(49.98%)在诊断后接受含蒽环类药物的化疗作为初始治疗。
本研究提供了韩国局部和晚期 STS 的流行病学、治疗模式和结局的见解,可作为未来改善 STS 患者临床结局的基础数据。